Viruses need to access host cells to propagate and spread. The plasma membrane constitutes a physical barrier to infection, and enveloped viruses evolved specialized surface proteins (also termed envelope‐ or glycoproteins) to overcome this obstacle. These proteins mediate binding of viruses to host cells and subsequent fusion of the viral and a limiting host cell membrane, which allows the delivery of viral nucleic acid and protein into the host cell cytoplasm ([Harrison, 2008](#b27){ref-type="ref"}). The first essential step in the entry cascade is the cognate binding of viral envelope proteins to components of the host cell surface, termed viral receptors ([Harrison, 2008](#b27){ref-type="ref"}). Receptor binding can limit infection efficiency, for example when receptor expression levels and/or receptor affinity of the viral envelope protein are low ([Bannert *et al*., 2000](#b5){ref-type="ref"}). To circumvent this limitation, viruses can also engage cellular attachment factors, which promote viral binding to the cell surface and thus increase the possibility of successful receptor engagement and infectious entry. For instance, HIV can incorporate cellular proteins into its envelope, which interact with binding partners on target cells and thereby augment viral attachment and entry ([Cantin *et al*., 2005](#b10){ref-type="ref"}).

Dendritic cells are professional antigen presenting cells, which can initiate primary and stimulate memory immune responses. Immature dendritic cells are particularly adept in antigen capture, while mature dendritic cells efficiently present antigen to T cells. The major dendritic cell subsets in human blood are myeloid and plasmacytoid dendritic cells, which can produce high amounts of IL‐12 and IFN‐α respectively ([Wu and KewalRamani, 2006](#b58){ref-type="ref"}). Dendritic cells of myeloid origin also line body surfaces and attachment of HIV to these cells in the anogenital mucosa might play a prominent role in the sexual transmission of HIV, the major route of viral spread, as discussed below. Initial evidence for an important role of myeloid dendritic cells in HIV transmission came from cell culture studies demonstrating that mature, myeloid dendritic cells isolated from blood boost HIV infection of cocultured T cells without becoming infected (*trans*‐infection) ([Cameron *et al*., 1992](#b9){ref-type="ref"}). Subsequent studies extended these findings to monocyte‐derived immature and mature dendritic cells (reviewed by [Wu and KewalRamani, 2006](#b58){ref-type="ref"}), model systems for myeloid dendritic cells in blood and tissues. A molecular basis for HIV *trans*‐infection by immature dendritic cells was provided by Geijtenbeek and colleagues, who showed that these cells express the lectin DC‐SIGN (for dendritic cell‐specific intercellular adhesion molecule 3‐grabbing nonintegrin), and that DC‐SIGN binds to glycans on HIVEnv and facilitates *trans*‐infection of adjacent T cells ([Geijtenbeek *et al*., 2000](#b19){ref-type="ref"}). Based on these findings, and taking into account the natural ability of dendritic cells to migrate from the periphery into lymphoid tissue, it was proposed that sexually transmitted HIV hijacks submucosal dendritic cells via DC‐SIGN to promote its dissemination, a concept referred to as the Trojan horse model ([Geijtenbeek *et al*., 2000](#b19){ref-type="ref"}). Reports that other viruses and non‐viral pathogens exploit DC‐SIGN on dendritic cells to augment their spread ([Table 1](#t1){ref-type="table"}) suggested that the Trojan horse model might be paradigmatic for the host invasion by a broad spectrum of pathogens. Recent work challenged important features of this model, but also demonstrated new mechanisms how pathogens can target DC‐SIGN to propagate.

###### 

Microbial ligands of DC‐SIGN.

  Pathogen                              Reference
  ------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Viruses:                              
   Human immunodeficiency virus         [Curtis *et al*. (1992](#b1006){ref-type="ref"}); [Geijtenbeek *et al*. (2000)](#b19){ref-type="ref"}
   Human T‐cell leukaemia virus         [Ceccaldi *et al*. (2006](#b1004){ref-type="ref"})
   Human herpesvirus 8                  [Rappocciolo *et al*. (2006b)](#b1019){ref-type="ref"}
   Human cytomegalovirus                [Halary *et al*. (2002](#b9011){ref-type="ref"})
   Herpes simplex virus                 [de Jong *et al*. (2008a)](#b1012){ref-type="ref"}
   Influenza virus                      [Wang *et al*. (2008a)](#b1011){ref-type="ref"}
   Measles virus                        [de Witte *et al*. (2006](#b1021){ref-type="ref"})
   Dengue virus                         [Navarro‐Sanchez *et al*. (2003](#b1017){ref-type="ref"})
   West Nile virus                      [Martina *et al*. (2008](#b1016){ref-type="ref"}); [Davis *et al*. (2006)](#b1007){ref-type="ref"}
   Sindbis virus                        [Klimstra *et al*. (2003](#b1013){ref-type="ref"})
   Hepatitis C virus                    [Pöhlmann *et al*. (2003](#b1018){ref-type="ref"}); [Lozach *et al*. (2003](#b1015){ref-type="ref"}); [Gardner *et al*. (2003](#b1009){ref-type="ref"})
   Ebola virus                          [Alvarez *et al*. (2002)](#b1){ref-type="ref"}; [Pöhlmann *et al*. (2003](#b1018){ref-type="ref"})
   Marburg virus                        [Marzi *et al*. (2004](#b1010){ref-type="ref"})
   SARS‐coronavirus                     [Marzi *et al*. (2004)](#b1010){ref-type="ref"}; [Yang *et al*. (2004](#b1022){ref-type="ref"})
  Bacteria:                             
    *Mycobacterium tuberculosis*        [Tailleux *et al*. (2003](#b1020){ref-type="ref"}); [Geijtenbeek *et al*. (2003](#b9000){ref-type="ref"})
    *Mycobacterium leprae*              [Barreiro *et al*. (2006](#b1001){ref-type="ref"})
    *Helicobacter pylori*               [Bergman *et al*. (2004](#b1002){ref-type="ref"})
    *Streptococcus pneumoniae*          [Koppel *et al*. (2005](#b1014){ref-type="ref"})
  Fungi:                                
    *Candida albicans*                  [Cambi *et al*. (2003](#b1003){ref-type="ref"})
  Protozoa:                             
    *Leishmania* spp.                   [Colmenares *et al*. (2002)](#b1005){ref-type="ref"}
  Parasites:                            
    *Schistosoma mansoni* egg antigen   [van Die *et al*. (2003](#b1008){ref-type="ref"})

In the present review, we will introduce potential consequences of HIV interactions with DC‐SIGN and other immune cell lectins and we will discuss recent developments in the field. Our focus will be on HIV, since important mechanisms underlying DC‐SIGN‐dependent augmentation of pathogen spread have been established with this virus, and apply to other viruses as well.

DC‐SIGN on dendritic cells and HIV *trans*‐infection: progress and pitfalls {#ss2}
===========================================================================

DC‐SIGN is expressed by monocyte‐derived dendritic cells (MDDCs) and by dendritic cells in mucosal and lymphoid tissues, although concerns have been raised that DC‐SIGN‐positive cells found in some tissues might indeed be macrophages ([Granelli‐Piperno *et al*., 2005](#b20){ref-type="ref"}; [Gurney *et al*., 2005](#b26){ref-type="ref"}). In addition, expression of DC‐SIGN outside the macrophage/dendritic cell lineage has been noted; for instance a subset of B cells expresses DC‐SIGN ([Rappocciolo *et al*., 2006a](#b46){ref-type="ref"}). DC‐SIGN is a type II transmembrane protein, in which the following domains have been identified: a cytoplasmic domain, a transmembrane domain, a neck‐region and a lectin domain. The cytoplasmic domain contains motifs involved in receptor internalization and signalling, while the neck region facilitates DC‐SIGN tetramerization, which is required for high‐affinity ligand binding ([Serrano‐Gomez *et al*., 2008](#b48){ref-type="ref"}; [Tabarani *et al*., 2009](#b52){ref-type="ref"}). Finally, the lectin domain, which requires calcium for its structural integrity (C‐type), binds to high‐mannose and fucose residues on pathogens and cellular proteins ([Guo *et al*., 2004](#b25){ref-type="ref"}).

*Trans*‐infection was reported to depend on DC‐SIGN‐mediated binding and cellular uptake of HIV into dendritic cells ([Geijtenbeek *et al*., 2000](#b19){ref-type="ref"}; [Kwon *et al*., 2002](#b35){ref-type="ref"}), followed by intracellular transport of virions to sites of dendritic cell--T cell contact, termed infectious synapses ([McDonald *et al*., 2003](#b41){ref-type="ref"}) ([Fig. 1](#f1){ref-type="fig"}). At the T cell site of the infectious synapse CD4 and coreceptor are concentrated ([McDonald *et al*., 2003](#b41){ref-type="ref"}), resulting in the establishment of a microenvironment ideally suited for HIV *trans*‐infection. Collectively, these results suggest that HIV exploits mechanisms normally used for antigen presentation by dendritic cells to increase its infectivity for adjacent T cells. In the following, we will review recent work examining key features of this concept.

![Consequences of HIV attachment to DC‐SIGN on dendritic cells. Engagement of DC‐SIGN on dendritic cells can promote infection of adjacent target cells in two ways. First, DC‐SIGN can augment productive infection of dendritic cells, a process termed *cis*‐infection, and progeny virions released from the dendritic cells can infect nearby target cells. Second, dendritic cells can transfer captured virus (input virus) to adjacent target cells without becoming productively infected, a pathway termed *trans*‐infection. *Trans*‐infection occurs at infectious synapses, contact points between dendritic cells and T cells, and HIV might traffic to infectious synapses via intracellular and extracellular routes. The latter trafficking pathway might involve transport of HIV in intracellular but surface connected compartments. In addition, viruses bound to DC‐SIGN can be internalized and processed for MHC presentation. Finally, DC‐SIGN engagement can trigger signal transduction, which modulates TLR‐dependent cytokine production.](CMI-12-1553-g001){#f1}

Sticky and sweet: several lectins mediate HIV binding to dendritic cells {#ss3}
------------------------------------------------------------------------

Initial work suggested that DC‐SIGN was required for efficient MDDC‐mediated HIV *trans*‐infection ([Geijtenbeek *et al*., 2000](#b19){ref-type="ref"}). Albeit this finding is controversial ([Gummuluru *et al*., 2003](#b24){ref-type="ref"}; [Boggiano *et al*., 2007](#b7){ref-type="ref"}), a number of reports indicate that blockade of DC‐SIGN by either antibodies, carbohydrates ([Baribaud *et al*., 2002](#b6){ref-type="ref"}; [Wu *et al*., 2002](#b59){ref-type="ref"}; [Wang *et al*., 2007a](#b56){ref-type="ref"}) or RNAi ([2004a](#b2){ref-type="ref"}, [2004b](#b3){ref-type="ref"}) indeed diminishes HIV *trans*‐infection ([Gurney *et al*., 2005](#b26){ref-type="ref"}). In addition, DC‐SIGN promotes HIV dissemination by migratory cells from cervical explants ([Hu *et al*., 2004](#b31){ref-type="ref"}). However, the indicated role of DC‐SIGN in HIV *trans*‐infection by dendritic cells is not universal. Thus, different types of dendritic cells employ different C‐type lectins, DC‐SIGN, mannose receptor (MR) and langerin, as well as CD4 for binding to HIV Env, and dendritic cell maturation shifts Env capture from lectins to CD4 ([Turville *et al*., 2002](#b53){ref-type="ref"}). Accordingly, DC‐SIGN is believed to contribute to HIV *trans*‐infection mediated by immature but not by mature dendritic cells ([Izquierdo‐Useros *et al*., 2007](#b32){ref-type="ref"}; [Wang *et al*., 2007a](#b56){ref-type="ref"}), although one study reached a different conclusion ([Baribaud *et al*., 2002](#b6){ref-type="ref"}), and coexpression of CD4 was found to diminish DC‐SIGN‐mediated *trans*‐infection, possibly by facilitating uptake and transport of HIV into late endosomal compartments ([Wang *et al*., 2007b](#b55){ref-type="ref"}). The list of lectins involved in HIV attachment to dendritic cells was recently expanded to include the C‐type lectin DCIR (dendritic cell immunoreceptor), but the relative contributions of DC‐SIGN and DCIR to HIV *trans*‐infection remain to be established ([Lambert *et al*., 2008](#b36){ref-type="ref"}). Finally, HIV attachment to dendritic cells can also proceed in a lectin‐ and CD4‐independent fashion ([de Witte *et al*., 2007a](#b13){ref-type="ref"}; [Hatch *et al*., 2009](#b28){ref-type="ref"}; [Izquierdo‐Useros *et al*., 2009](#b33){ref-type="ref"}). Thus, dendritic cells have multiple means to capture HIV, and the prevalent mode of viral binding depends on the origin and the maturation status of the cells.

DC‐SIGN‐dependent HIV uptake and trafficking in dendritic cells: degradation versus trans‐infection {#ss4}
---------------------------------------------------------------------------------------------------

Kwon and colleagues found that HIV transfer to T cells by DC‐SIGN‐positive cells was dependent on lectin‐mediated viral internalization into low pH compartments ([Kwon *et al*., 2002](#b35){ref-type="ref"}), in which viral infectivity was preserved ([Geijtenbeek *et al*., 2000](#b19){ref-type="ref"}; [Kwon *et al*., 2002](#b35){ref-type="ref"}) ([Fig. 1](#f1){ref-type="fig"}). An LL motif in the cytoplasmic tail of DC‐SIGN facilitates ligand endocytosis by DC‐SIGN ([Engering *et al*., 2002](#b16){ref-type="ref"}). However, a contribution of the LL motif to HIV transmission by DC‐SIGN expressing cell lines was not observed by a subsequent study ([Burleigh *et al*., 2006](#b8){ref-type="ref"}), and the role of a low pH compartment in HIV *trans*‐infection has been questioned ([Nobile *et al*., 2005](#b44){ref-type="ref"}; [Wang *et al*., 2007a](#b56){ref-type="ref"}). The former observation is in agreement with work demonstrating that DC‐SIGN contributes to HIV uptake into dendritic cells, but targets the majority of internalized virions for degradation and MHC presentation ([2004](#b42){ref-type="ref"}, [2006](#b43){ref-type="ref"}) ([Fig. 1](#f1){ref-type="fig"}). The identification of LSP1 as a cellular binding partner of the cytoplasmic tail of DC‐SIGN further supports such a scenario ([Smith *et al*., 2007](#b50){ref-type="ref"}). Thus, normal expression of LSP1 diverts HIV into the proteasome of dendritic cells, while LSP1 knock‐down increases *trans*‐infection ([Smith *et al*., 2007](#b50){ref-type="ref"}).

Regardless of the role of DC‐SIGN, it is undisputed that HIV is efficiently taken up into dendritic cells and important differences between immature and mature dendritic cells have been noted ([Frank *et al*., 2002](#b17){ref-type="ref"}; [Wang *et al*., 2007a](#b56){ref-type="ref"}). Thus, virions taken up into mature dendritic cells accumulate in large endocytic compartments, which resemble structures seen in macrophages upon HIV uptake by macropinocytosis ([Wang *et al*., 2007a](#b56){ref-type="ref"}). In comparison, virions associated with immature dendritic cells are mostly found close to the cell surface, with only a few virions being present in intracellular vesicles, which exhibit a clathrin‐coat ([Wang *et al*., 2007a](#b56){ref-type="ref"}). Notably, the ability to traffic HIV into deep intracellular compartments was found to correlate with protection of virus from proteases, and inhibitors of intracellular trafficking and cytoskeleton integrity were shown to inhibit *trans*‐infection ([2007a](#b56){ref-type="ref"}, [2008b](#b57){ref-type="ref"}), in agreement with the proposal that HIV traffics intracellularly, via a tetraspanin‐sorting pathway, to infectious synapses ([Garcia *et al*., 2005](#b18){ref-type="ref"}). In contrast, a separate study postulated that virions reach infectious synapses exclusively by transport on the cell surface instead of travelling along intracellular routes ([Cavrois *et al*., 2007](#b11){ref-type="ref"}). In agreement with this scenario, it was reported that HIV is routed towards the infectious synapse in a surface accessible, intracellular compartment ([Yu *et al*., 2008](#b60){ref-type="ref"}). Irrespective of the route of HIV trafficking, there is ample evidence that HIV capture does not preserve viral infectivity ([Turville *et al*., 2004](#b54){ref-type="ref"}; [Nobile *et al*., 2005](#b44){ref-type="ref"}; [Burleigh *et al*., 2006](#b8){ref-type="ref"}; [Wang *et al*., 2007a](#b56){ref-type="ref"}), with the initially postulated conservation of viral infectivity likely being due to productive infection of the transmitting cells ([Nobile *et al*., 2005](#b44){ref-type="ref"}; [Burleigh *et al*., 2006](#b8){ref-type="ref"}).

Collectively, HIV *trans*‐infection driven by dendritic cells is short lived (hours) and DC‐SIGN on immature dendritic cells contributes to this process in at least two ways: DC‐SIGN promotes capture and potentially uptake of virions subsequently transferred to T cells. In addition, DC‐SIGN seems to stimulate the formation of infectious synapses by a so far incompletely understood mechanism ([Arrighi *et al*., 2004a](#b2){ref-type="ref"}).

DC‐SIGN signals dendritic cells to transmit HIV {#ss5}
-----------------------------------------------

Recent studies revealed a novel facet of HIV interactions with DC‐SIGN on dendritic cells, the modulation of the immune response. It was demonstrated that binding of HIV to MDDCs induces ERK‐dependent signal transduction, which correlates with production of the immunosuppressive cytokine IL‐10 and compromised maturation of dendritic cells ([Shan *et al*., 2007](#b49){ref-type="ref"}). These effects were dependent on appropriate Env glycosylation and on C‐type lectin expression, and a role of DC‐SIGN was postulated ([Shan *et al*., 2007](#b49){ref-type="ref"}). Removal of mannose‐rich glycans from Env improved immunogenicity of the protein ([Banerjee *et al*., 2009](#b4){ref-type="ref"}), further pointing towards a role of mannose‐specific lectins in immune responses shaped by dendritic cells. In agreement with these findings, HIV binding to DC‐SIGN on dendritic cells was demonstrated to induce signalling via the Rho guanine nucleotide--exchange factor LARG and the small GTPase RhoA, which results in aberrant dendritic cell maturation ([Hodges *et al*., 2007](#b30){ref-type="ref"}). Thus, the cells fail to upregulate CD86 and MHC II but readily form infectious synapses with T cells ([Hodges *et al*., 2007](#b30){ref-type="ref"}), indicating that HIV signalling via DC‐SIGN compromises the immune function of dendritic cells and simultaneously primes the cells for *trans*‐infection. A separate study showed that binding of HIV to DC‐SIGN induces signals via a multi‐protein complex, including the kinase Raf‐1, which modulates TLR‐induced cytokine production by regulating acetylation of the NFκB subunit p65 ([Gringhuis *et al*., 2007](#b21){ref-type="ref"}). Interestingly, activation of Raf‐1 was dependent on LARG and RhoA and on the carbohydrate profile of the pathogen bound to DC‐SIGN. Thus, HIV and *Mycobacterium tuberculosis*, which bound to DC‐SIGN via high‐mannose residues, activated Raf‐1 signalling and induced production of a cytokine profile different from that triggered by *Helicobacter pylori*, which was due to recognition of fucose containing structures and did not involve Raf‐1 activation ([Gringhuis *et al*., 2009](#b22){ref-type="ref"}) ([1](#f1){ref-type="fig"}, [2](#f2){ref-type="fig"}). Finally, signalling via TLR8 and DC‐SIGN was required for NFκB‐dependent recruitment of the transcription factor pTEF‐b to the viral promoter, and thus for the generation of full‐length HIV transcripts in dendritic cells -- a prerequisite for productive infection ([Gringhuis *et al*., 2010](#b23){ref-type="ref"}) ([Fig. 2](#f2){ref-type="fig"}). However, HIV infection of dendritic cells is inefficient compared with T cells and macrophages (reviewed by [Wu and KewalRamani, 2006](#b58){ref-type="ref"}), and a contribution of this mechanism to viral spread *in vivo* remains to be established. In sum, DC‐SIGN has signalling capacity, which can be exploited by pathogens to modulate immune responses and to establish productive infection of dendritic cells and adjacent target cells.

![HIV induces signalling via DC‐SIGN, which promotes dendritic cell infection and release of immunosuppressive cytokines. Triggering TLR‐3 or TLR‐7 induces NFκB activation. Concomitant engagement of DC‐SIGN by HIV triggers Raf‐1‐dependent signalling, which results in phosphorylation of Ser276 of the NFκB subunit p65. Phosphorylation of Ser276 in turn induces acetylation of lysines in p65, which increases and prolongs transcription of the IL‐10 gene. IL‐10 inhibits the Th1‐mediated response and incapacitates the antigen presentation capabilities of dendritic cells. Induction of TLR‐8 signalling by HIV activates NFκB and allows synthesis of short HIV transcripts. Parallel triggering of DC‐SIGN signalling by HIV induces phosphorylation of the p65 subunit of NFκB at Ser276. This phosphorylation event allows recruitment of the transcription‐elongation factor pTEF‐b to the HIV promoter, which phosphorylates RNA polymerase II at Ser2. Phosphorylation increases processivity of the enzyme and thus allows synthesis of full‐length HIV transcripts.](CMI-12-1553-g002){#f2}

Langerin on langerhans cells: a roadblock to HIV transmission? {#ss6}
==============================================================

Langerhans cells are located in the top layer of the mucosa and are most likely the first cell type to come in contact with sexually transmitted HIV. Langerhans cells are DC‐SIGN‐negative but express CD4 and the C‐type lectin langerin ([Soilleux and Coleman, 2001](#b51){ref-type="ref"}). Pioneer work by de Witte and colleagues provided evidence that langerin constitutes a defence mechanism against HIV invasion ([de Witte *et al*., 2007b](#b15){ref-type="ref"}). Thus, langerin binds to Env and targets bound virions into Birbeck granules, an intracellular compartment specific to Langerhans cells, where the virus is degraded ([de Witte *et al*., 2007b](#b15){ref-type="ref"}). Counter‐intuitively, however, C‐type lectins were reported to play a minor role in HIV entry into vaginal Langerhans cells ([Hladik *et al*., 2007](#b29){ref-type="ref"}), and examination of skin explants inoculated with HIV indicated HIV infection of Langerhans cells, but not other types of dendritic cells, and transfer of virus from Langerhans cells to T cells ([Kawamura *et al*., 2008](#b34){ref-type="ref"}). The latter observations suggest that infection of Langerhans cells might be an important early event in HIV transmission. Such a scenario can be reconciled with the findings of de Witte and colleagues, when taking into account that the barrier imposed by langerin can be overcome by high doses of virus ([de Witte *et al*., 2007b](#b15){ref-type="ref"}) and that TNF‐α, produced upon genital coinfections, like candida albicans, might increase permissiveness of Langerhans cells to HIV infection ([de Jong *et al*., 2008b](#b12){ref-type="ref"}) -- hypotheses that should be tested in animal models.

DC‐SIGN: target for many viruses {#ss7}
================================

DC‐SIGN is targeted by different viruses which all contain envelope proteins with an appropriate glycan signature. Three major consequences of viral engagement of DC‐SIGN have been described: first, DC‐SIGN can function as a *bona fide* entry receptor. In this case, expression of DC‐SIGN is sufficient to render cells susceptible to infection. Such a scenario has been suggested, e.g. for dendritic cell infection by human herpesvirus 8 (HHV‐8) ([Rappocciolo *et al*., 2008](#b45){ref-type="ref"}), the causative agent of Karposi sarcoma and for Ebolavirus infection of T cells ([Alvarez *et al*., 2002](#b1){ref-type="ref"}). However, it is technically challenging to discriminate between entry mediated solely by DC‐SIGN (receptor function) and entry augmented by DC‐SIGN but facilitated by a coexpressed receptor, a process termed *cis*‐infection ([Lee *et al*., 2001](#b37){ref-type="ref"}). In fact, DC‐SIGN most likely functions as an attachment factor in the context of Ebolavirus entry into lymphoid cells ([Marzi *et al*., 2007](#b40){ref-type="ref"}). Second, DC‐SIGN might augment *cis*‐infection, as described above. DC‐SIGN‐driven *cis*‐infection has been established for dengue virus infection of dendritic cells, which are important early targets of this pathogen ([Lozach *et al*., 2005](#b39){ref-type="ref"}). Polymorphisms in the DC‐SIGN gene were shown to impact disease development, suggesting that *cis*‐infection might facilitate viral spread in patients ([Sakuntabhai *et al*., 2005](#b47){ref-type="ref"}). Third, DC‐SIGN can promote *trans*‐infection of target cells. While this route has first been established for HIV, *trans*‐infection of several viruses by DC‐SIGN has been demonstrated, including Measles virus ([de Witte *et al*., 2008](#b14){ref-type="ref"}) and Ebolavirus ([Alvarez *et al*., 2002](#b1){ref-type="ref"}), and might promote transmission of these pathogens. Whether DC‐SIGN engagement by viruses other than HIV also modulates cytokine release and thus impacts the establishment of an immune response remains to be determined.

Conclusions {#ss8}
===========

Detailed information on the processes ensuing exposure of anogenital mucosa to sexually transmitted HIV is indispensable to understand viral dissemination and pathogenesis and to develop effective antiviral strategies. There is continued and well founded belief that dendritic cells play an important role in the establishment of HIV infection. However, the idea of the role of DC‐SIGN in HIV interactions with dendritic cells has changed considerably ([Fig. 1](#f1){ref-type="fig"}). It has become clear that dendritic cells have several means to bind and transfer HIV to cells, with C‐type lectins being one of them. In addition, an appreciable protection of HIV from antiviral agents upon attachment to dendritic cells is under discussion, and the concept of long‐term storage and subsequent regurgitation of infectious HIV by dendritic cells had to be abandoned. On the other hand, DC‐SIGN‐mediated HIV *trans*‐infection, although found to be a short‐lived process, and *cis*‐infection might promote viral amplification in the genital mucosal, which could be critical for the establishment of the primary infection. Conversely, langerin on Langerhans cells was discovered to target HIV for degradation, suggesting a barrier function of this lectin. Finally, intriguing new findings revealed a signalling capacity of DC‐SIGN (and other lectins), which is exploited by HIV to compromise immune defences and to promote its spread. Vaccine development should therefore encompass the optimization of the glycan profiles of candidate substances, and new strategies for immunotherapy can be envisioned. Ultimately, key concepts need to be evaluated in improved cell culture systems and animal models for sexual transmission of HIV. An important but often overlooked parameter determining outcome and significance of such experiments is the source of the virus. Glycosylation of HIV depends on the producer cell type, and viruses generated in macrophages are unlikely to be detected efficiently by C‐type lectins on mucosal dendritic cells ([Lin *et al*., 2003](#b38){ref-type="ref"}). Consequently, these viruses might overcome the mucosal barrier with different efficiency and potentially by employing different strategies compared with viruses generated in T cells -- and similar considerations apply to most if not all other DC‐SIGN ligands.
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